Gothenburg, Sweden – November 13, 2024 – VERIGRAFT, a pioneer in personalized tissue therapies, has today publicly launched a crowdfunding campaign on Capital Cell to accelerate future treatments for vascular disease. This groundbreaking initiative seeks to raise funds to advance its innovative technology, which offers a safer, more personalized approach to transplantation and addresses critical global shortages of tissue therapies.
“VERIGRAFT’s pioneering tissue therapy technology offers a transformative path for treating chronic venous insufficiency and other vascular diseases, providing new hope for millions who currently have no lasting cure. By delivering a personalized, effective solution, they are turning the potential for relief into reality for those in need,” says Bryan Kluck, Interventional Cardiologist, Endovascular Interventionalist and Vascular Medicine Specialist at Lehigh Valley Hospital, PA, USA.
VERIGRAFT’s revolutionary technology involves creating personalized blood vessels from the patient’s own blood-derived material, reducing the risk of complications. With funds from this campaign, the company aims to expand clinical trials and further develop their pipeline of personalized tissue grafts.
“We’re super excited to invite the community to support our mission,” says Petter Björquist, CEO of VERIGRAFT. “Every contribution helps bring us closer to delivering customized, life-saving solutions to patients in need of transplants.”
Be part of the healthcare revolution – help us bring hope and healing to millions of people with VERIGRAFT’s innovative therapies.
Learn more and invest in VERIGRAFT’s campaign on Capital Cell using this link:
https://capitalcell.com/en/campaign/verigraft/
For more information, please contact:
invest@verigraft.com